4 years ago

HexagonFab Secures £1.9 Million for Handheld Biopharmaceutical Analytics Device

  • HexagonFab, a University of Cambridge spin-off, has secured £1.9 million in seed funding led by Cambridge Enterprise, Parkwalk, NGVC, R42 Group, and private investors

  • The funding will be used to grow the team and complete development of their first product, Bolt, a handheld device for molecular binding analytics in biopharmaceutical research and manufacturing

  • Bolt utilizes a graphene-based semiconductor sensor to detect proteins, antibodies, and small molecules, enabling faster and more convenient analysis of biomolecular interactions

  • The investment aims to accelerate drug development and lead to better and safer drugs in the future.

      • ProblemHealthcare

      "Developing next-generation biopharmaceuticals is hampered by high costs and a significant risk of failure, limiting access to better analytical tools for researchers."

      Solution

      "HexagonFab offers Bolt, an affordable handheld device using a graphene-based sensor to simplify biomolecular interaction analysis. It provides rapid, real-time data on protein and small molecule interactions, accelerating drug development and making it more accessible."

      Covered on